These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24752512)

  • 1. Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility.
    Greenberg SA
    Muscle Nerve; 2014 Oct; 50(4):488-92. PubMed ID: 24752512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis.
    Larman HB; Salajegheh M; Nazareno R; Lam T; Sauld J; Steen H; Kong SW; Pinkus JL; Amato AA; Elledge SJ; Greenberg SA
    Ann Neurol; 2013 Mar; 73(3):408-18. PubMed ID: 23596012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis.
    Pluk H; van Hoeve BJ; van Dooren SH; Stammen-Vogelzangs J; van der Heijden A; Schelhaas HJ; Verbeek MM; Badrising UA; Arnardottir S; Gheorghe K; Lundberg IE; Boelens WC; van Engelen BG; Pruijn GJ
    Ann Neurol; 2013 Mar; 73(3):397-407. PubMed ID: 23460448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis.
    Tawara N; Yamashita S; Zhang X; Korogi M; Zhang Z; Doki T; Matsuo Y; Nakane S; Maeda Y; Sugie K; Suzuki N; Aoki M; Ando Y
    Ann Neurol; 2017 Apr; 81(4):512-525. PubMed ID: 28318044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of inclusion body myositis.
    Greenberg SA
    Curr Opin Rheumatol; 2013 Nov; 25(6):753-62. PubMed ID: 24067380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center.
    Felice KJ; Whitaker CH; Wu Q; Larose DT; Shen G; Metzger AL; Barton RW
    Neuromuscul Disord; 2018 Aug; 28(8):660-664. PubMed ID: 30001928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of sex, age at onset, and anti-cN1A antibodies on sporadic inclusion body myositis.
    Yamashita S; Tawara N; Sugie K; Suzuki N; Nishino I; Aoki M
    J Neurol Sci; 2024 Sep; 464():123164. PubMed ID: 39126732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patients.
    Levy D; Nespola B; Giannini M; Felten R; Severac F; Varoquier C; Rinagel M; Korganow AS; Martin T; Poindron V; Maurier F; Chereih H; Bouldoires B; Hervier B; Lenormand C; Chatelus E; Geny B; Sibilia J; Arnaud L; Gottenberg JE; Meyer A
    Rheumatology (Oxford); 2022 Feb; 61(2):756-763. PubMed ID: 33974078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis.
    Salam S; Dimachkie MM; Hanna MG; Machado PM
    Clin Exp Rheumatol; 2022 Feb; 40(2):384-393. PubMed ID: 35225226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis.
    Amlani A; Choi MY; Tarnopolsky M; Brady L; Clarke AE; Garcia-De La Torre I; Mahler M; Schmeling H; Barber CE; Jung M; Fritzler MJ
    Front Immunol; 2019; 10():745. PubMed ID: 31024569
    [No Abstract]   [Full Text] [Related]  

  • 11. Determination of cN1A Autoantibodies by Cell-Based Immunofluorescence Cytochemistry.
    Yamashita S; Tawara N
    Methods Mol Biol; 2019; 1901():89-94. PubMed ID: 30539570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis.
    Paul P; Liewluck T; Ernste FC; Mandrekar J; Milone M
    Muscle Nerve; 2021 Apr; 63(4):490-496. PubMed ID: 33373040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathies.
    Ikenaga C; Findlay AR; Goyal NA; Robinson S; Cauchi J; Hussain Y; Wang LH; Kershen JC; Beson BA; Wallendorf M; Bucelli RC; Mozaffar T; Pestronk A; Weihl CC
    Ann Clin Transl Neurol; 2021 Mar; 8(3):571-578. PubMed ID: 33556224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.
    Herbert MK; Stammen-Vogelzangs J; Verbeek MM; Rietveld A; Lundberg IE; Chinoy H; Lamb JA; Cooper RG; Roberts M; Badrising UA; De Bleecker JL; Machado PM; Hanna MG; Plestilova L; Vencovsky J; van Engelen BG; Pruijn GJ
    Ann Rheum Dis; 2016 Apr; 75(4):696-701. PubMed ID: 25714931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.
    Lilleker JB; Rietveld A; Pye SR; Mariampillai K; Benveniste O; Peeters MT; Miller JA; Hanna MG; Machado PM; Parton MJ; Gheorghe KR; Badrising UA; Lundberg IE; Sacconi S; Herbert MK; McHugh NJ; Lecky BR; Brierley C; Hilton-Jones D; Lamb JA; Roberts ME; Cooper RG; Saris CG; Pruijn GJ; Chinoy H; van Engelen BG;
    Ann Rheum Dis; 2017 May; 76(5):862-868. PubMed ID: 28122761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Accuracy of Anti-CN1A on the Diagnosis of Inclusion Body Myositis. A Hierarchical Bivariate and Bayesian Meta-analysis.
    Mavroudis I; Knights M; Petridis F; Chatzikonstantinou S; Karantali E; Kazis D
    J Clin Neuromuscul Dis; 2021 Sep; 23(1):31-38. PubMed ID: 34431799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.
    Lloyd TE; Christopher-Stine L; Pinal-Fernandez I; Tiniakou E; Petri M; Baer A; Danoff SK; Pak K; Casciola-Rosen LA; Mammen AL
    Arthritis Care Res (Hoboken); 2016 Jan; 68(1):66-71. PubMed ID: 25892010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.
    Yeker RM; Pinal-Fernandez I; Kishi T; Pak K; Targoff IN; Miller FW; Rider LG; Mammen AL;
    Ann Rheum Dis; 2018 May; 77(5):714-719. PubMed ID: 29363513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic role of anti-cN1A autoantibodies in sporadic inclusion body myositis.
    Yamashita S; Tawara N; Zhang Z; Nakane S; Sugie K; Suzuki N; Nishino I; Aoki M
    J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1018-1024. PubMed ID: 37451693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel serology testing for sporadic inclusion body myositis: disease-specificity and diagnostic utility.
    Herbert MK; Pruijn GJ
    Curr Opin Rheumatol; 2015 Nov; 27(6):595-600. PubMed ID: 26285103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.